Tirzepatide Halves Glaucoma Risk Compared to GLP-1 Drugs Alone in 84,000 Diabetic Patients
Tirzepatide was associated with 50% lower POAG risk (RR 0.50), 41% lower OHTN (RR 0.59), and 46% lower glaucoma treatment need (RR 0.54) compared to GLP-1 RAs in 83,698 matched T2D patients.
Quick Facts
What This Study Found
Tirzepatide vs GLP-1 RA: POAG RR 0.50 (0.34-0.74); OHTN RR 0.59 (0.40-0.88); glaucoma treatment RR 0.54 (0.45-0.64). Consistent with metformin/insulin subgroups and individual GLP-1 RA comparisons. 41,849 matched pairs.
Key Numbers
How They Did This
Retrospective cohort using 71 US healthcare organizations (June 2022-May 2025), 1:1 propensity matching for demographics, comorbidities, medications, and ophthalmic encounters, with RR calculations.
Why This Research Matters
Glaucoma is a leading cause of irreversible blindness affecting 80M people. A 50% risk reduction from a commonly prescribed drug could prevent millions of cases.
The Bigger Picture
The GIP receptor activation unique to tirzepatide may provide additional neuroprotective effects in the eye beyond GLP-1 agonism alone.
What This Study Doesn't Tell Us
Retrospective observational. Cannot prove causation. Short follow-up since tirzepatide approval (2022). Glaucoma diagnosis by codes may miss subclinical cases.
Questions This Raises
- ?Does GIP receptor activation directly protect retinal ganglion cells?
- ?Should ophthalmologists recommend tirzepatide for patients at glaucoma risk?
- ?Would tirzepatide eye drops provide direct ocular protection?
Trust & Context
- Key Stat:
- 50% less glaucoma Tirzepatide users had half the risk of developing primary open-angle glaucoma compared to GLP-1-only drug users
- Evidence Grade:
- Very large propensity-matched cohort with consistent subgroup analyses. Strong signal but observational.
- Study Age:
- Published in 2025 using data June 2022-May 2025.
- Original Title:
- Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes.
- Published In:
- American journal of ophthalmology, 283, 120-128 (2026)
- Authors:
- Hong, Alexander T(2), Lin, Forest(2), Baxter, Sally(2), Weinreb, Robert N
- Database ID:
- RPEP-15305
Evidence Hierarchy
Frequently Asked Questions
Could tirzepatide protect against glaucoma?
This large study found tirzepatide users had 50% lower glaucoma risk than GLP-1-only drug users. The dual mechanism (GIP+GLP-1) may provide extra eye protection.
Should I switch to tirzepatide to protect my eyes?
This is early evidence — discuss with your doctor. If you have diabetes and glaucoma risk factors, tirzepatide may offer advantages over GLP-1-only drugs, but this needs confirmation.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15305APA
Hong, Alexander T; Lin, Forest; Baxter, Sally; Weinreb, Robert N. (2026). Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes.. American journal of ophthalmology, 283, 120-128. https://doi.org/10.1016/j.ajo.2025.12.003
MLA
Hong, Alexander T, et al. "Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes.." American journal of ophthalmology, 2026. https://doi.org/10.1016/j.ajo.2025.12.003
RethinkPeptides
RethinkPeptides Research Database. "Tirzepatide is Associated With Reduced Risk of Primary Open-..." RPEP-15305. Retrieved from https://rethinkpeptides.com/research/hong-2026-tirzepatide-is-associated-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.